Skip to content

SUPPLEMENTATION WITH BETA GLUCAN AND ADAPTATIVE RESPONSE.

SUPPLEMENTATION WITH FERMENTED AND BALANCED FOOD WITH BETA GLUCAN FAVORS THE INNATE AND ADAPTATIVE RESPONSE OF PATIENTS ADMITTED TO A MEDICAL CLINIC WARD? A RANDOMIZED TRIAL

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06545149
Enrollment
44
Registered
2024-08-09
Start date
2024-10-31
Completion date
2025-12-31
Last updated
2024-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinical Course

Brief summary

Abstract: Studies demonstrate that the use of nutritional supplements containing beta-glucans stimulates the immune system, modulates inflammatory activity, and promotes so-called immune training. Beta-glucans are prebiotics that stimulate the growth and activity of gastrointestinal microbiota and inhibit pathogen growth. Nutritional intervention is crucial for patients' positive evolution, and providing a supplement with highly bioavailable nutrients can make a difference in their nutritional, metabolic, and immune status. Therefore, the study aims to verify the effectiveness of the innate and adaptive immune response to a nutritionally balanced fermented food, containing oral or enteral beta-glucans, in patients treated at 3 Emergency Care Units in São José do Rio Preto, São Paulo, Brazil. This is a prospective randomized study with a characteristic design involving patients treated in the medical wards of 3 Emergency Care Unit. The following assessments will be conducted: Global Subjective Assessment for adults and Mini Nutritional Assessment for the elderly, Sociodemographic, and Laboratory Evaluation.

Interventions

DIETARY_SUPPLEMENTBioNutri AR-1,

intervention with fermented and nutritionally balanced food twice a day

Sponsors

Kaiser Clinic and Hospital
CollaboratorOTHER
Federal University of São Paulo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

Patients admitted to the medical clinic ward

Exclusion criteria

Patients unable to swallow

Design outcomes

Primary

MeasureTime frame
length of hospital stayduring hospitalization

Secondary

MeasureTime frame
need for readmissionup to 24 weeks
need for ICUup to 24 weeks

Contacts

Primary ContactFERNANDO SABIA TALLO, PhD
fstallo@unifesp.br+55 11 971554018

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026